Changchun High-Tech Industry (SHE:000661) applied with China's drug regulator to conduct clinical trials for GenSci161 injection.
The drug is intended for connective tissue disease-associated interstitial lung disease, according to a Tuesday filing with the Shenzhen bourse.
Shares of the drug manufacturer rose 2% in recent trade.